I. Methods

Determination of tumor content
The tumor cell content was estimated by visual inspection on full slides of the respective lymphoma block used for the molecular analyses with help of the immunohistochemical stains for CD20 and at least one T-cell marker. Confusion with reactive B-cell-areas should not have caused significant wrong estimations as usually the lymphoma was more or less completely effacing the preexisting B-cell areas and as significant areas with small reactive follicles can be recognized cytologically even within the CD20-staining.
The OncoScan FFPE Express assay copy number and somatic mutation determination
DNAs from formalin-fixed paraffin-embedded material were hybridized on the MIP-assay using
Oncoscan FFPE Express custom service (Affymetrix, Santa Clara, USA). Copy number determination of MIP-assay has been previously described. 1 Briefly, MIP probes are oligonucleotides in which the two end sequences are complementary to two adjacent genomic sequences; these two ends anneal to the genomic DNA in an inverted fashion with a single base between them (generally the site of a single nucleotide polymorphism; SNP). In copy number analysis, genomic DNA is hybridized to the MIP probe and the reaction split into two separate tubes containing paired nucleotide mixes. 2 Amplification and ligation allows circularization of the MIP probe. The probes are then amplified, labeled, detected and quantified by hybridization to tag microarrays. Gains and losses were defined by the use of a trial version of Nexus 6.0 beta Discovery Edition (Biodiscovery, El Segundo, USA) that integrates the genomic identification of significant targets in Cancer (GISTIC) algorithm for identifying significant regions of common genomic aberrations as well as the Allele specific Copy number Analysis of tumors (ASCAT) algorithm for addressing sample aneuploidy and mosaicism. The average resolution was of ~9 Kb/probe for whole genome backbone and ~3 Kb/probe for intragenic regions.
OncoScan FFPE Express also analyzes ~300 somatic mutations in relevant cancer genes.
These files are generated from the raw CEL files as part of the primary data analysis process using Affymetrix software. Each sample has a score for each assay (each assay interrogates one previously described mutation). According to manufacturer's instructions a score of 9 or higher indicates that an assay is a valid somatic mutation for that sample. According to this criterion, PIK3CA_pR88Q_c263G_A, FBXW7_pR278X_c832C_T, ABL1_pF359V_c1075T_G, NOTCH1_pL1586P_c4757T_C, PTEN_p_c165_minus_2A_C and PTEN_pQ110X_c328C_T mutations were found. No mutation detected by MIP assay was confirmed by Sanger sequencing.
Array-CGH
Microarray analysis has been performed using the Human Genome CGH Microarray 244A 
Mutations
Non-synonymous mutations were tested for their functional consequences in silico by using different aminoacid substitution prediction algorithms, including SIFT (Sorting Intolerant From Tolerant) and PolyPhen-2 (Polymorphism Phenotyping).
Statistical analyses
Statistical analyses were performed using PASW Statistics software version 18 (SPSS Inc., Chicago, USA). Chi-Square or Fisher´s exact tests were used to determine the significance of any differences between the clinical variables in samples with genomic aberrations vs. wild type. Overall survival (OS) was defined as the time from diagnosis to date of most recent followup. All statistical tests were considered significant at P≤0.05.
Informed consent
The study was performed in the framework of the BFM-NHL trial, for which central and local institutional review board approvals were obtained and according to the guidelines of the MMML † The case pFL8 presents starry sky pattern-Burkitt like pattern; ** Nijmegen-breakage syndrome; differentiation between relapse and second malignancy not possible (no molecular genetics); another relapse DD second malignancy (no molecular genetics) 8 years after first lymphoma; alive; & The case pFL3 shows the diffuse growth in 90% of the biopsy as this is an infiltration of the intestinal wall. A secondary colonization of preexisting follicles of the Payer Plaques cannot be ruled out. Nevertheless, the histopathology nor an additional staining for FDCnetworks does not allow to differentiate in this case between secondary involvement and focal true follicular growth.
$ The architecture and extension of the follicular component did not resemble secondary colonization of preexisting follicles; ^BCL2 expression data of ten cases were previously published by Oschlies et al, 2010 Supplementary 
